1 / 5

Andreas Kannenberg, MD, PhD; Britta Zacharias, Dipl-Ing (FH); Eva Pröbsting, Dipl-Ing (FH), CPO

Benefits of microprocessor-controlled prosthetic knees to limited community ambulators: Systematic review. Andreas Kannenberg, MD, PhD; Britta Zacharias, Dipl-Ing (FH); Eva Pröbsting, Dipl-Ing (FH), CPO. Aim

hwoodland
Download Presentation

Andreas Kannenberg, MD, PhD; Britta Zacharias, Dipl-Ing (FH); Eva Pröbsting, Dipl-Ing (FH), CPO

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Benefits of microprocessor-controlled prosthetic knees to limited community ambulators: Systematic review Andreas Kannenberg, MD, PhD; Britta Zacharias, Dipl-Ing (FH); Eva Pröbsting, Dipl-Ing (FH), CPO

  2. Aim • Review literature to determine potential benefits of microprocessor-controlled knees (MPKs) for limited community ambulators (Medicare Functional Classification Level [MFCL]-2). • Relevance • Benefits of MPKs are well established in community ambulators (MFCL-3) with transfemoral amputation (TFA).

  3. Method • Searched 10 scientific databases for clinical trials with MPKs. • Identified six relevant publications with 57 subjects with TFA and MFCL-2 mobility grade. • Rated methodological quality using criteria from Cochrane Review on prosthetic components. • 4 studies = moderate. • 2 studies = low.

  4. Results • MPK use may significantly: • Reduce uncontrolled falls up to 80%. • Improve indicators of fall risk. • Performance-based outcome measures suggest that MFCL-2 ambulators using MPKs may walk: • 14%–25% faster on level ground. • 20% quicker on uneven surfaces. • 30% faster when descending a slope.

  5. Conclusion • Trial fittings may be used to determine whether or not individuals with TFA and MFCL-2 mobility grade benefit from MPK use. • Criteria for patient selection and assessment of trial fitting success or failure are proposed.

More Related